Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
May 28, 2024 16:05 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 16:10 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Clinical ink announces GlucoseReady™
April 23, 2024 08:00 ET
|
Clinical Ink
Winston Salem, NC, April 23, 2024 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, today announced the launch of GlucoseReady™, a fully integrated GCP compliant digital...
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
April 15, 2024 08:05 ET
|
Organovo, Inc.
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Conte
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
April 09, 2024 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
Rezdiffra is the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) First patients have received Rezdiffra via Madrigal’s specialty pharmacy network ...
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
April 05, 2024 09:17 ET
|
Spherix Global Insights
EXTON, PA, April 05, 2024 (GLOBE NEWSWIRE) -- As the first treatment to gain FDA approval for metabolic dysfunction-associated steatohepatitis (MASH), Madrigal Pharmaceuticals’ Rezdiffra...
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 26, 2024 06:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
March 21, 2024 07:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
March 14, 2024 17:18 ET
|
Global Liver Institute
Washington, DC, March 14, 2024 (GLOBE NEWSWIRE) -- Today, Global Liver Institute (GLI) recognizes the importance of the first approval by the U.S. Food and Drug Administration (FDA) of a medication...
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
February 29, 2024 08:00 ET
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...